My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden
 Register / submit abstract

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

København, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

   Stockholm, Sweden

I-01 Nurul Azrin Abd Rahman
A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study
Wednesday 09:50-11:15
I-02 Mahmoud Abdelwahab
Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis
Wednesday 09:50-11:15
I-03 Khaled Abduljalil
Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice
Wednesday 09:50-11:15
I-04 Anson Abraham
Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design?
Wednesday 09:50-11:15
I-05 Ahmad Abuhelwa
Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression
Wednesday 09:50-11:15
I-06 Ahmed Aliyu Abulfathi
External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package
Wednesday 09:50-11:15
I-07 Oliver Ackaert
Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects
Wednesday 09:50-11:15
I-08 Bambang Adiwijaya
Component score models of HAMD were more predictive than total score models
Wednesday 09:50-11:15
I-09 Jae Eun Ahn
Longitudinal Model-Based Meta-Analysis for Liver Biomarkers and Biopsy Endpoints in Patients with Non-Alcoholic Fatty Liver Disease
Wednesday 09:50-11:15
I-10 Maurice Ahsman
A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy
Wednesday 09:50-11:15
I-11 Marie Alexandre
Modeling viral rebound in HIV therapeutic vaccine studies
Wednesday 09:50-11:15
I-12 Joachim Almquist
Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation
Wednesday 09:50-11:15
I-13 Jokha AL-Qassabi
Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment
Wednesday 09:50-11:15
I-14 Hesham Al-Sallami
The use of a Bayesian dosing tool to optimise enoxaparin treatment: a pilot clinical study
Wednesday 09:50-11:15
I-15 Vincent Aranzana-Climent
Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii
Wednesday 09:50-11:15
I-16 Million Arefayene
Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011)
Wednesday 09:50-11:15
I-17 Leticia Arrington
An R package for Automated Generation of Item Response Theory Model NONMEM Control File
Wednesday 09:50-11:15
I-18 Usman Arshad
A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients
Wednesday 09:50-11:15
I-19 Muhammad Waqar Ashraf
Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers
Wednesday 09:50-11:15
I-20 Magnus Åstrand
nonmem2R: An R-package for Visual Predictive Checks and Goodness-of-fit Plots
Wednesday 09:50-11:15
I-21 Ioanna Athanasiadou
Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis
Wednesday 09:50-11:15
I-22 Linda Aulin
Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents
Wednesday 09:50-11:15
I-23 Ahmad Rami Ayoun Alsoud
Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy
Wednesday 09:50-11:15
I-24 Geraldine Ayral
Straightforward dose adaptation simulations with Simulx, the simulator of the MonolixSuite
Wednesday 09:50-11:15
I-25 LE Ba Hai
Population pharmacokinetic model of sorafenib and application to a case report
Wednesday 09:50-11:15
I-26 Junjie Ding
Pharmacometric drug adherence approach and its application in a clinical setting
Wednesday 09:50-11:15
I-27 Vanessa Baier
Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism
Wednesday 09:50-11:15
I-28 Pavel Balazki
A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models.
Wednesday 09:50-11:15
I-29 Violeta Balbas-Martinez
Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease
Wednesday 09:50-11:15
I-30 Irina Baltcheva
ggPMX: an open-source R package for pharmacometric model diagnostic plots
Wednesday 09:50-11:15
I-31 Maddlie Bardol
Population pharmacokinetics of fentanyl in very preterm infants
Wednesday 09:50-11:15
I-32 Christian Bartels
Getting a better description of treatment effects for time to event data using PKPD modelling
Wednesday 09:50-11:15
I-33 Roberta Bartolucci
Optimal design of paediatric clinical trials: the Macitentan case study
Wednesday 09:50-11:15
I-34 Carla Bastida Fernández
Assessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients
Wednesday 09:50-11:15
I-35 Francesco Bellanti
Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs
Wednesday 09:50-11:15
I-36 Amina Bensalem
Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis
Wednesday 09:50-11:15
I-37 Linnea Bergenholm
Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data
Wednesday 09:50-11:15
I-38 Aliénor Bergès
Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case
Wednesday 09:50-11:15
I-39 Martin Bergstrand
Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling
Wednesday 09:50-11:15
I-40 Jan Berkhout
Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia
Wednesday 09:50-11:15
I-41 Julie Bertrand
Model-based approach for group sequential and adaptive designs in parallel and cross-over bioequivalence studies
Wednesday 09:50-11:15
I-42 Robert Bies
On the Multilemma of reproducibility: Stochastic or Deterministic or Stochastic and Deterministic
Wednesday 09:50-11:15
I-43 Bruno Bieth
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer
Wednesday 09:50-11:15
I-44 Roberto Bizzotto
Conditional linear mixed-effect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study
Wednesday 09:50-11:15
I-45 Irina Bondareva
Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data
Wednesday 09:50-11:15
I-46 Guillaume Bonnefois
A new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies
Wednesday 09:50-11:15
I-47 Elisa Borella
Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia
Wednesday 09:50-11:15
I-48 Agnieszka Borsuk-De Moor
The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits
Wednesday 09:50-11:15
I-49 Thomas Bouillon
Model predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation.
Wednesday 09:50-11:15
I-50 Marion Bouillon-Pichault
Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma
Wednesday 09:50-11:15
I-51 Muriel Boulton
What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)?
Wednesday 09:50-11:15
I-52 Ari Brekkan Viggosson
Model based support to biosimilarity assessment planning – A case study of pegfilgrastim
Wednesday 09:50-11:15
I-53 Astrid Broeker
Parameter uncertainty in small datasets – evaluation approaches at their limit
Wednesday 09:50-11:15
I-54 Vincent Buchheit
Data scientists for improving efficiency and quality of quantitative clinical pharmacology analyses
Wednesday 09:50-11:15
I-55 Núria Buil Bruna
Can monocyte counts predict future drug-induced neutropenia toxicities?
Wednesday 09:50-11:15
I-56 David Busse
Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling
Wednesday 09:50-11:15
I-57 Antonio Cabal
Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery
Wednesday 09:50-11:15
I-58 Unai Caballero
Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris
Wednesday 09:50-11:15
I-59 Elisa Calvier
Alirocumab population pharmacokinetics in Chinese patients using priors
Wednesday 09:50-11:15
I-60 Tim Cardilin
Tumor Static Exposure for anticancer combinations in early drug discovery
Wednesday 09:50-11:15
I-61 Fernando Carreño
Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia
Wednesday 09:50-11:15
I-62 Jantine Brussee
Model-based dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults
Wednesday 09:50-11:15
I-63 Blesson Chacko
Why patients may not benefit from effective oncology drugs
Wednesday 09:50-11:15
I-64 Dong Woo Chae
Predictive model of postoperative nausea and vomiting in patients treated with Fentanyl-based intravenous patient controlled analgesia
Wednesday 09:50-11:15
I-65 Anne Chain
A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia
Wednesday 09:50-11:15
I-66 Anna Chan Kwong
Bridging studies: handling covariates models using the Prior approach
Wednesday 09:50-11:15
I-67 Christophe Chassagnole
A precision dosing application for docetaxel in metastatic prostate cancer
Wednesday 09:50-11:15
I-68 Estelle Chasseloup
Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data
Wednesday 09:50-11:15
I-69 Jonathan Chauvin
Novel user-friendly applications for dose individualization of sunitinib and imatinib
Wednesday 09:50-11:15
I-70 Alexia Chauzy
Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria
Wednesday 09:50-11:15
I-71 Viji Chelliah
Mechanistic models of cancer-immune cycle and immunotherapies
Wednesday 09:50-11:15
I-72 Lu Chen
Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis
Wednesday 09:50-11:15
I-73 Maxwell Tawanda Chirehwa
Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients
Wednesday 09:50-11:15
I-74 Siri Kalyan Chirumamilla
Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients
Wednesday 09:50-11:15
I-75 Palang Chotsiri
Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity
Wednesday 09:50-11:15
I-76 Emmanuelle Comets
Conditional non-parametric bootstrap for non-linear mixed effect models
Wednesday 09:50-11:15
I-77 Valerie Cosson
Target-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy
Wednesday 09:50-11:15
I-78 Perrine Courlet
Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV.
Wednesday 09:50-11:15
I-79 Sinziana Cristea
Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiology-based pharmacokinetics approach
Wednesday 09:50-11:15
I-80 Salvatore D'Agate
Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Pre-term Neonates
Wednesday 09:50-11:15
I-81 Kim Dao
Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells
Wednesday 09:50-11:15
I-82 Mailys De Sousa Mendes
Transporter inhibition: modelling in-vitro Transwell assays
Wednesday 09:50-11:15
I-83 Eva Maria del Amo Paez
Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes
Wednesday 09:50-11:15
I-84 Francesca Del Bene
Intratympanic drug administration: a challenge for PK modelling
Wednesday 09:50-11:15
I-85 Laurence Del Frari
Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures
Wednesday 09:50-11:15
I-86 Oleg Demin Jr
Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling
Wednesday 09:50-11:15
I-87 Laure Deyme
Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue
Wednesday 09:50-11:15
I-88 Sofie Dhaese
The use of optimal experimental design to inform a clinical trial on non-linearity of piperacillin clearance in critically ill patients.
Wednesday 09:50-11:15
I-89 Richard Dimelow
PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously
Wednesday 09:50-11:15